Back to top

CervoMed completes enrollment in neflamapimod study

CervoMed (CRVO) announced that it has completed enrollment in the Phase 2a study of neflamapimod for the treatment of nfvPPA, a type of FTD. Interi...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

CervoMed Inc. (CRVO)